The trial aims to assess the safety and efficacy of tralokinumab 300mg administered biweekly as a single agent.

LEO Pharma has reported outcomes from the 16-week interim analysis of the Phase IIIb ADHAND trial of tralokinumab for hand atopic dermatitis (AD).

Treatment with dupilumab is associated with weight gain in about two thirds of adults with atopic dermatitis over 3-6 months, according to a retrospective study.

Apogee Therapeutics (NASDAQ:APGE) stock drops despite mid-stage trial success for APG777 in treating atopic dermatitis. Read ...

The antibody treatment could compete with Sanofi’s Dupixent and Eli Lilly’s Ebgylss, while offering the potential for less ...

Investing.com -- Apogee (NASDAQ: APOG) Therapeutics, Inc. (NASDAQ: APGE) stock surged 24% on Monday after the clinical-stage biotechnology company announced positive 16-week data from its Phase 2 APEX ...

AD and psoriasis were once thought to be opposites in terms of immune response, with AD linked to a Th2-dominant pathway and ...

Apogee Therapeutics, Inc.'s APG777 shows promising week-16 efficacy and dosing potential, targeting the AT market. Click for ...

Arcutis Biotherapeutics Inc. (NASDAQ:ARQT) is one of the most promising stocks according to Wall Street analysts. On June 26, ...

[A]lthough our findings found that there is insufficient evidence to suggest that dupilumab use is associated with joint pain, the prevalence of joint pain observed among patients treated with ...

Apogee Therapeutics shares soared in premarket trading Monday after the company said it received positive trial data for its atopic dermatitis treatment. Shares traded 36% higher ahead of the morning ...

In a recent regulatory development, the Subject Expert Committee (SEC) under the Dermatology and Allergy division of the ...